Skip to content
ClinCalc Pro
Menu
Class III Antiarrhythmic (Iodine-containing)

Amiodarone Hydrochloride

Brand names: Cordarone X

Amiodarone hydrochloride is the salt form of the class III antiarrhythmic amiodarone, available as oral and intravenous preparations for serious atrial and ventricular tachyarrhythmias.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It mainly blocks cardiac potassium channels to prolong the action potential and refractory period, with additional sodium and calcium channel blocking and beta-adrenergic antagonist actions.

Prescribing in practice

  • Cumulative thyroid, hepatic, pulmonary and ocular toxicity together with QT prolongation mandates baseline checks, periodic monitoring and avoidance of unnecessary QT-prolonging combinations.
  • The extremely long half-life means drug interactions, including with warfarin and digoxin, continue for weeks after discontinuation.
  • The intravenous route may cause profound hypotension and venous irritation, so dilute appropriately and prefer central administration for continued infusion.

Monitoring

Check thyroid and liver function before treatment and periodically thereafter, with ECG monitoring and chest or eye review where clinically indicated.

Counselling the patient

  • Protect skin from sunlight to reduce photosensitivity reactions.
  • Report new cough, breathlessness, visual disturbance or signs of an over- or under-active thyroid.
  • Avoid grapefruit juice and inform other prescribers about long-lasting interactions.

Evidence & guidelines

Use is supported by NICE guidance on arrhythmia management and resuscitation algorithms, with MHRA communications underlining the need for organ-toxicity monitoring.

Reference: NICE NG196 (Atrial fibrillation, 2021 updated 2024); ESC Guidelines on AF (2020 updated 2024); MHRA Drug Safety Update (amiodarone thyroid, 2015); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.